TLR4 and neoplasm: A previous study designed a folate‐modified liposomal NPs (FA‐sLip/OVA/MPLA) that attaches to blood IgM for “hitchhiking” to the spleen, delivering the co‐loaded tumor model antigen OVA to MZB cells in the spleen, while releasing the TLR4 agonist (MPLA) immunoadjuvant to induce antigen‐specific humoral immunity and cytotoxic T lymphocyte responses.[32] Li et al.